Olema Oncology to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) will participate in three upcoming healthcare investor conferences, with fireside chats scheduled from November 30 through December 2, 2026.
The Evercore chat is November 30 at 2:35 p.m. ET in Miami; Citi’s is December 1 at 1:00 p.m. ET in Miami; and Piper Sandler’s is December 2 at 1:30 p.m. ET in New York. Webcasts and recordings will be available at ir.olema.com, as permitted by each event host.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
9th Annual Evercore Healthcare Conference
Date and Time: November 30, 2026 at 2:35 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Citi's 2026 Global Healthcare Conference
Date and Time: December 1, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Piper Sandler 38th Annual Healthcare Conference
Date and Time: December 2, 2026 at 1:30 p.m. ET
Format: Fireside Chat
Location: New York, NY
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com